51 related articles for article (PubMed ID: 16239434)
1. The novel DNA methylation inhibitor zebularine is effective against the development of murine T-cell lymphoma.
Herranz M; Martín-Caballero J; Fraga MF; Ruiz-Cabello J; Flores JM; Desco M; Marquez V; Esteller M
Blood; 2006 Feb; 107(3):1174-7. PubMed ID: 16239434
[TBL] [Abstract][Full Text] [Related]
2. Zebularine significantly sensitises MEC1 cells to external irradiation and radiopharmaceutical therapy when administered sequentially in vitro.
Bryan JN; Kumar SR; Jia F; Balkin ER; Lewis MR
Cell Biol Int; 2014 Feb; 38(2):187-97. PubMed ID: 24323360
[TBL] [Abstract][Full Text] [Related]
3. Postnatal administration of S-adenosylmethionine restores developmental AHR activation-induced deficits in CD8+ T cell function during influenza A virus infection.
Post CM; Myers JR; Winans B; Lawrence BP
Toxicol Sci; 2023 Feb; 192(2):233-46. PubMed ID: 36847456
[TBL] [Abstract][Full Text] [Related]
4. The Protective Effect of Zebularine, an Inhibitor of DNA Methyltransferase, on Renal Tubulointerstitial Inflammation and Fibrosis.
Koh ES; Kim S; Son M; Park JY; Pyo J; Kim WY; Kim M; Chung S; Park CW; Kim HS; Shin SJ
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430531
[TBL] [Abstract][Full Text] [Related]
5. Examination of epigenetic inhibitor zebularine in treatment of skin wounds in healthy and diabetic mice.
Sass P; Sosnowski P; Kamińska J; Deptuła M; Skoniecka A; Zieliński J; Rodziewicz-Motowidło S; Pikuła M; Sachadyn P
J Tissue Eng Regen Med; 2022 Dec; 16(12):1238-1248. PubMed ID: 36350668
[TBL] [Abstract][Full Text] [Related]
6. Regenerative Drug Discovery Using Ear Pinna Punch Wound Model in Mice.
Sosnowski P; Sass P; Słonimska P; Płatek R; Kamińska J; Baczyński Keller J; Mucha P; Peszyńska-Sularz G; Czupryn A; Pikuła M; Piotrowski A; Janus Ł; Rodziewicz-Motowidło S; Skowron P; Sachadyn P
Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631437
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic inhibitor zebularine activates ear pinna wound closure in the mouse.
Sass P; Sosnowski P; Podolak-Popinigis J; Górnikiewicz B; Kamińska J; Deptuła M; Nowicka E; Wardowska A; Ruczyński J; Rekowski P; Rogujski P; Filipowicz N; Mieczkowska A; Peszyńska-Sularz G; Janus Ł; Skowron P; Czupryn A; Mucha P; Piotrowski A; Rodziewicz-Motowidło S; Pikuła M; Sachadyn P
EBioMedicine; 2019 Aug; 46():317-329. PubMed ID: 31303499
[TBL] [Abstract][Full Text] [Related]
8. The relationship between DNA methylation and
Lai J; Wang H; Luo Q; Huang S; Lin S; Zheng Y; Chen Q
Oncotarget; 2017 Dec; 8(65):108610-108623. PubMed ID: 29312555
[TBL] [Abstract][Full Text] [Related]
9. Mutagen Synergy: Hypermutability Generated by Specific Pairs of Base Analogs.
Ang J; Song LY; D'Souza S; Hong IL; Luhar R; Yung M; Miller JH
J Bacteriol; 2016 Oct; 198(20):2776-83. PubMed ID: 27457718
[TBL] [Abstract][Full Text] [Related]
10. Creation of zebularine-resistant human cytidine deaminase mutants to enhance the chemoprotection of hematopoietic stem cells.
Ruan H; Qiu S; Beard BC; Black ME
Protein Eng Des Sel; 2016 Dec; 29(12):573-582. PubMed ID: 27160178
[TBL] [Abstract][Full Text] [Related]
11. Identification of the collagen type 1 α 1 gene (COL1A1) as a candidate survival-related factor associated with hepatocellular carcinoma.
Hayashi M; Nomoto S; Hishida M; Inokawa Y; Kanda M; Okamura Y; Nishikawa Y; Tanaka C; Kobayashi D; Yamada S; Nakayama G; Fujii T; Sugimoto H; Koike M; Fujiwara M; Takeda S; Kodera Y
BMC Cancer; 2014 Feb; 14():108. PubMed ID: 24552139
[TBL] [Abstract][Full Text] [Related]
12. 3-D DNA methylation phenotypes correlate with cytotoxicity levels in prostate and liver cancer cell models.
Gertych A; Oh JH; Wawrowsky KA; Weisenberger DJ; Tajbakhsh J
BMC Pharmacol Toxicol; 2013 Feb; 14():11. PubMed ID: 23394161
[TBL] [Abstract][Full Text] [Related]
13. Reversibility of membrane N-glycome of HeLa cells upon treatment with epigenetic inhibitors.
Horvat T; Deželjin M; Redžić I; Barišić D; Herak Bosnar M; Lauc G; Zoldoš V
PLoS One; 2013; 8(1):e54672. PubMed ID: 23336012
[TBL] [Abstract][Full Text] [Related]
14. Hypomethylating therapy in an aggressive stroma-rich model of pancreatic carcinoma.
Shakya R; Gonda T; Quante M; Salas M; Kim S; Brooks J; Hirsch S; Davies J; Cullo A; Olive K; Wang TC; Szabolcs M; Tycko B; Ludwig T
Cancer Res; 2013 Jan; 73(2):885-96. PubMed ID: 23204224
[TBL] [Abstract][Full Text] [Related]
15. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.
Juergens RA; Wrangle J; Vendetti FP; Murphy SC; Zhao M; Coleman B; Sebree R; Rodgers K; Hooker CM; Franco N; Lee B; Tsai S; Delgado IE; Rudek MA; Belinsky SA; Herman JG; Baylin SB; Brock MV; Rudin CM
Cancer Discov; 2011 Dec; 1(7):598-607. PubMed ID: 22586682
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic-based therapies in cancer: progress to date.
Song SH; Han SW; Bang YJ
Drugs; 2011 Dec; 71(18):2391-403. PubMed ID: 22141383
[TBL] [Abstract][Full Text] [Related]
17. DNA demethylating antineoplastic strategies: a comparative point of view.
Amatori S; Bagaloni I; Donati B; Fanelli M
Genes Cancer; 2010 Mar; 1(3):197-209. PubMed ID: 21779447
[TBL] [Abstract][Full Text] [Related]
18. Hypermethylation of PTGER2 confers prostaglandin E2 resistance in fibrotic fibroblasts from humans and mice.
Huang SK; Fisher AS; Scruggs AM; White ES; Hogaboam CM; Richardson BC; Peters-Golden M
Am J Pathol; 2010 Nov; 177(5):2245-55. PubMed ID: 20889571
[TBL] [Abstract][Full Text] [Related]
19. Enhanced growth inhibition by combined DNA methylation/HDAC inhibitors in lung tumor cells with silenced CDKN2A.
Chen M; Voeller D; Marquez VE; Kaye FJ; Steeg PS; Giaccone G; Zajac-Kaye M
Int J Oncol; 2010 Oct; 37(4):963-71. PubMed ID: 20811718
[TBL] [Abstract][Full Text] [Related]
20. Determination of hypersensitivity to genotoxic agents among Escherichia coli single gene knockout mutants.
Becket E; Chen F; Tamae C; Miller JH
DNA Repair (Amst); 2010 Sep; 9(9):949-57. PubMed ID: 20674514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
